Oconics director Ari Pullinen has a career in Information technology than spans more than three decades in Finland and Australia. Ari has experience in industries that include engineering and paper manufacture, banking, pharmaceutical, manufacturing and biotechnology, Clinical Research organisations including clinical field trials.
In Australia, Ari has worked with leading organisations such as Adelaide Bank, Faulding Pharmaceuticals and Novozymes Biopharma AU/GroPep Limited, which has operations in Australia, Europe and China. Ari has an in-depth knowledge and experience of qualifying IT systems to achieve 21 CFR Part 11 pharmaceutical regulatory compliance. Ari is also currently a director of biotechnology company GroPep Bioreagents Pty Ltd.